NASDAQ:PTGX
Protagonist Therapeutics, Inc
Protagonist Therapeutics, Inc's revenue fell 89.4% in fiscal 2025 to $46.0M while operating margin fell to −343.6%. Free cash flow was $56.1M, 121.9% of revenue, and the diluted share count fell 2.3%.Summary generated from Protagonist Therapeutics, Inc's SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$46.0M
Revenue growth−89.4%
Revenue, 5-yr CAGR+10.0%
Gross marginn/a
Operating margin−343.6%
Net margin−282.8%
ROICn/a
Return on equity−20.2%
Debt / equityn/a
Free cash flow$56.1M
FCF margin121.9%
Share count change−2.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 27 | 27 | 60 | 434 | 46 |
| Operating income | −126 | −131 | −94 | 253 | −158 |
| Net income | −126 | −127 | −79 | 275 | −130 |
| Free cash flow | −109 | −109 | −71 | 183 | 56 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
Jun 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026 - 8-KResults of operations and financial condition
May 5, 2026 - DEF 14AProxy statement
Apr 28, 2026